Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00.

Alvotech (NASDAQ:ALVO – Get Free Report) is expected to issue its quarterly earnings data after the market closes on ...

Alvotech (ALVO) announced the appointment of Balaji Prasad as chief strategy officer. He was most recently a director and equities analyst at ...

Thursday announced the acquisition of Xbrane Biopharma AB’s R&D operations and a biosimilar candidate, establishing a footprint in the Swedish life science sector.

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the approval of AVT03, a proposed biosimilar of Amgen’s AMGN Prolia ...

Dr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...

In trading on Monday, shares of Alvotech (Symbol: ALVO) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $11.25 per share. By comparison, the current ...

Treatment table ALVO Menuet 4-00 has been designed to support the patient during all surgical procedures and operations: general surgery, vascular surgery, endoscopy, neurosurgery, gynecology and ...